Top broker says buy ResMed and this ASX 200 share

Ord Minnett was impressed with their quarterly updates from last month.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A number of companies have released their quarterly updates in recent weeks.

Analysts at Ord Minnett have been running the rule over these updates and have picked out two ASX 200 shares that impressed enough to be rated as buys.

Here's what the broker is saying about them:

Happy shareholders clap and smile as they listen to a company earnings report.

Image source: Getty Images

ResMed Inc. (ASX: RMD)

The first ASX 200 share that impressed is ResMed. It is a developer, manufacturer, distributor, and marketer of medical device and cloud-based software applications targeting the management of sleep apnoea.

Ord Minnett described ResMed's result as "strong" and has bumped its earnings estimates higher to reflect this and its positive outlook. It said:

The company delivered a strong September quarter result, with 11% revenue growth translating to 35% earnings per share growth. Revenues were 3% ahead of consensus due to higher rates of flow generator growth. ‍ The gross margin of 59.2% aligned with expectations, while operating expenses were slightly ahead of forecasts. ‍ Net operating cash flow increased by 14% compared to the previous corresponding period, despite higher inventory due to rebalancing sea versus air freight. Net debt fell, while the value of share buyback program was boosted.

ResMed upped it FY25 EPS guidance thanks to jump higher flow generator revenues. Revenue growth for the current quarter is forecast at 10%. We forecast the company will be able to generate annualised EPS growth of 13% for the next few years, which justifies its current trading multiples. We ticked our price target up from $39.25 to $40.05 following the quarterly.

Whitehaven Coal Ltd (ASX: WHC)

As well as ResMed shares, Ord Minnett is tipping Whitehaven Coal as an ASX 200 share to buy following the recent flurry of quarterly updates.

It develops and operates metallurgical and thermal coal mines in New South Wales and Queensland. ‍

Much like ResMed, the broker highlights that Whitehaven Coal delivered a solid quarterly update last month. It said:

The company had a solid September quarter of production and sales, with all mines delivering as planned or better. Group performance in Q1FY25 included managed run-of-mine production of 9.7Mt, and total equity sales of 6.4Mt. Net debt was $1.2 billion. ‍ Queensland operations achieved strong production and productivity improvements at Blackwater and Daunia, with run-of-mine (ROM)production up 11% and sales up 13%. Average coal price increased to $259/t. ‍

New South Wales saw improved Narrabri production and focused on overburden removal. Run-of-mine production was down 12%, with equity sales down 16%. Average coal price was $211/t. ‍ Run-of-mine coal production is expected to increase in the second half of FY25. Global metallurgical coal production shortfalls and increased Indian demand are expected to drive prices higher, which will benefit Whitehaven. ‍

In light of this, it has put a buy rating and $9.00 price target on its shares.

Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

a couple consider the advice from a man with documents laid out on a table and the man holding a tablet in his hand.
Financial Shares

3 ASX 200 financial shares to sell: experts

ASX 200 financial shares are down 2.5% over six months and up 2.1% in 2026-to-date.

Read more »

A man rests his chin in his hands, pondering what is the answer?
Broker Notes

What is Morgans saying about Cochlear and Northern Star shares?

Here's what the broker is saying about these big names following their updates.

Read more »

A woman with a mobile phone in her hand looks sceptical with a puzzled expression on her face with an eyebrow raised and pursed lips.
Broker Notes

Buy, hold, sell: NextDC, Hub24, PLS Group shares

The market is pessimistic about the next round of talks between the US and Iran.

Read more »

A team of people giving the thumbs up sign.
Broker Notes

5 ASX 200 shares with renewed buy ratings this week

Brokers have indicated continuing confidence in Cochlear, REA, and several other ASX 200 shares.

Read more »

Buy now written on a red key with a shopping trolley on an Apple keyboard.
Broker Notes

Broker reiterates buy ratings on 2 ASX shares

These ASX shares remain worth watching.

Read more »

Sell buy and hold on a digital screen with a man pointing at the sell square.
Broker Notes

After more than quadrupling investors' money in a year, are PLS shares still a buy?

A leading analyst delivers his outlook for the soaring PLS share price.

Read more »

A young man wearing a bright yellow jumper and glasses purses his lips together and moves them to the side of his face as he wonders about something.
Broker Notes

Buy, hold, or sell? Life360, Iress, Lynas Rare Earths shares

Experts reveal their views.

Read more »

Worried woman calculating domestic bills.
Broker Notes

Why did this broker just lower its outlook on this ASX 200 stock?

Despite a lowered outlook, attractive upside remains.

Read more »